// A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors Cancer Immunology Research » Full Article
// A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies Cell Reports Medicine » Full Article
// Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody™), in metastatic castration resistant prostate cancer patients American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)   San Francisco, CA February 16-18, 2023. » Full Article
// LAVA-051, a novel bispecific gamma-delta T-cell engager (Gammabody™), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data  » Full Article
// Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager, confirmed in the clinical setting Submitted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting » Full Article
// Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future Frontiers in Immunology publication, Saura-Esteller, et al. » Full Article
// Phase I dose escalation of LAVA-051, a novel bispecific γδ-T cell engager (Gammabody™), in relapsed/refractory hematological malignancies European Hematological Association (EHA) 2022 Congress presentation Broijl, et al. » Full Article
// Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies 2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation Brojil, et al. » Full Article
// Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d Roeland Lameris, Jurjen M Ruben, Iris de Weerdt, Rob Roovers, Arnon P Kater, Thilo Riedl, Victoria Iglesias, Benjamin Winograd, Ton EP Adang, Tanja D de ... » Full Article
// A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia (Clinical Cancer Research) New publication in Clinical Cancer Research About the Potential of Targeting CD1d and Vγ9Vδ2-T cells to Treat CLL Authored by LAVA’s CSO Hans van der Vliet, MD, PhD » Full Article
// A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response (Nature Cancer) Antibody-mediated modulation of major histocompatibility complex (MHC) molecules, or MHC class I-like molecules, could constitute an effective immunotherapeutic approach. We describe how single-domain antibodies (VHH), ... » Full Article
// A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies (Cancer Immunology Research) Congrats to the LAVA team for the publication of exciting new data from a bispecific Vγ9Vδ2 T-cell engager directed against CD40 in Cancer Immunology Research. ... » Full Article
// Bispecific antibodies: a mechanistic review of the pipeline (Nature Reviews Drug Discovery) The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. BsAbs come in ... » Full Article